Literature DB >> 19734852

Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma.

Andrew E Horvai1, Sandy DeVries, Ritu Roy, Richard J O'Donnell, Frederic Waldman.   

Abstract

Liposarcoma represents a unique model insofar as some well-differentiated liposarcomas progress to non-lipogenic, so-called 'dedifferentiated,' forms. The well-differentiated and dedifferentiated family of liposarcomas demonstrates amplification of the chromosome subregion 12q13-q15 with resultant amplification of the MDM2 and CDK4 genes. However, the specific genetic changes that distinguish between well-differentiated and dedifferentiated liposarcomas are less well understood. To study the genetic changes in dedifferentiated liposarcomas, paired well-differentiated and dedifferentiated components of 29 tumors were analyzed separately by array-based comparative genomic hybridization. A bacterial artificial chromosome array at approximately 1-Mb resolution was used. The genetic changes were compared with clinical presentation, grade of the dedifferentiated component and overexpression of MDM2 and CDK4. Most tumors (n=21, 72%) were retroperitoneal, with both components present at initial diagnosis (n=25, 86%). Eight tumors (28%) were classified as low-grade dedifferentiation. In four cases (14%), a well-differentiated liposarcoma preceded the presentation of the dedifferentiated tumor by 1-5 years. 12q13-q15 was amplified in all tumors. Using unsupervised hierarchical clustering of copy-number changes, all but two tumors showed close similarities between well-differentiated and dedifferentiated components, and segregated as pairs. Dedifferentiated components had more total amplifications (P=0.008) and a trend for gain at 19q13.2, but no genetic changes were significant in distinguishing between the two components. High-level amplifications of 1p21-32 (n=7, 24%), 1q21-23 (n=9, 31%), 6q23-24 (n=6, 21%) and 12q24 (n=3, 10%) were common, but none significantly correlated with differentiation. Presentation and grade correlated with the frequency of changes at a number of genetic loci (P<0.001), whereas CDK4 immunostaining showed negative correlation with 12q13.13 amplification. The genotypic similarity, at the limit of the array's resolution, between components implies that most genetic changes precede phenotypic 'progression,' early in tumorigenesis. The relationship between genetic changes and presentation or grade may reflect differences in factors that control genomic instability or the background genotype of the tumor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19734852     DOI: 10.1038/modpathol.2009.119

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

Review 1.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

2.  c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.

Authors:  Stefano Sioletic; Jeffrey Czaplinski; Lan Hu; Jonathan A Fletcher; Christopher D M Fletcher; Andrew J Wagner; Massimo Loda; George D Demetri; Ewa T Sicinska; Eric L Snyder
Journal:  J Pathol       Date:  2014-08-01       Impact factor: 7.996

3.  Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma.

Authors:  Emily Z Keung; Kadir C Akdemir; Ghadah A Al Sannaa; Jeannine Garnett; Dina Lev; Keila E Torres; Alexander J Lazar; Kunal Rai; Lynda Chin
Journal:  J Clin Invest       Date:  2015-07-20       Impact factor: 14.808

4.  Can HMGI-C be used as an aid with MDM2 and CDK4 to differentiate liposarcoma subtypes from their mimics?

Authors:  Hanan Alshenawy
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-26       Impact factor: 4.553

Review 5.  Tumor heterogeneity: causes and consequences.

Authors:  Andriy Marusyk; Kornelia Polyak
Journal:  Biochim Biophys Acta       Date:  2009-11-18

6.  Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.

Authors:  Esma Saâda-Bouzid; Fanny Burel-Vandenbos; Dominique Ranchère-Vince; Isabelle Birtwisle-Peyrottes; Bruno Chetaille; Corinne Bouvier; Marie-Christine Château; Michel Peoc'h; Maxime Battistella; Audrey Bazin; Jocelyn Gal; Jean-François Michiels; Jean-Michel Coindre; Florence Pedeutour; Laurence Bianchini
Journal:  Mod Pathol       Date:  2015-09-04       Impact factor: 7.842

7.  Analysis of MYB oncogene in transformed adenoid cystic carcinomas reveals distinct pathways of tumor progression.

Authors:  Ana F Costa; Albina Altemani; Cristina García-Inclán; Florentino Fresno; Carlos Suárez; José L Llorente; Mario Hermsen
Journal:  Lab Invest       Date:  2014-04-14       Impact factor: 5.662

8.  Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.

Authors:  Su-Yang Liu; Nancy M Joseph; Ajay Ravindranathan; Bradley A Stohr; Nancy Y Greenland; Poonam Vohra; Elizabeth Hosfield; Iwei Yeh; Eric Talevich; Courtney Onodera; Jessica A Van Ziffle; James P Grenert; Boris C Bastian; Yunn-Yi Chen; Gregor Krings
Journal:  Mod Pathol       Date:  2016-06-03       Impact factor: 7.842

Review 9.  A challenging diagnosis of mesenchymal neoplasm of the colon: colonic dedifferentiated liposarcoma with lymph node metastases-a case report and review of the literature.

Authors:  Elia Guadagno; Roberto Peltrini; Loredana Stasio; Francesco Fiorentino; Luigi Bucci; Luigi Terracciano; Luigi Insabato
Journal:  Int J Colorectal Dis       Date:  2019-09-09       Impact factor: 2.571

10.  H3K9me3-mediated repression of KLF6: Discovering a novel tumor suppressor in liposarcoma using a systematic epigenomic approach.

Authors:  Emily Z Keung; Kunal Rai
Journal:  Mol Cell Oncol       Date:  2015-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.